XCancer

SPECT/CT Imaging for Dosimetry in 177Lu-PSMA-617 (Pluvicto) Therapy

Description:

This study is being performed to establish the association between absorbed dose to tumor and response and absorbed dose to normal organs and toxicity following Lu177-PSMA radioligand therapy

Sponsor:

University of Michigan Rogel Cancer Center

Phase:

N/A

Contacts:

James Pool

jampool@med.umich.edu

734-615-7391

Government Study Link:

NCT07096999 - Click here to see study on

ClinicalTrials.gov

Lu177-PSMA-617

Isotope(s):
Target(s):
  • PSMA
Ligand Class: Small Molecules
Chelator: DOTA